


0300

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



**RAW SEQUENCE LISTING**  
**ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/024,535  
Source: OIP  
Date Processed by STIC: 3/21/02

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

BEST AVAILABLE COPY

01PE

# Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 101024,535
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 _____ Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 _____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 _____ Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 _____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 _____ Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 _____ PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 _____ Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped  Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 _____ Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 _____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 _____ Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 <input checked="" type="checkbox"/> Use of <220>	Sequence(s) <u>All</u> missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 _____ PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 _____ Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	



**Does Not Comply** OIPE  
**Corrected Diskette Needed**

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/024,535

DATE: 03/21/2002

TIME: 10:06:35

Input Set : A:\SEQUENCE\_SMR1\_DSM.APP

Output Set: N:\CRF3\03212002\J024535.raw

→ The type of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.

3 <110> APPLICANT: INSTITUT PASTEUR  
5 <120> TITLE OF INVENTION: Therapeutic methods and compositions for the treatment  
6 of impaired interpersonal and behavioral disorders  
8 <130> FILE REFERENCE: BET 01/1201  
C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/024,535  
C--> 11 <141> CURRENT FILING DATE: 2001-12-21  
13 <150> PRIOR APPLICATION NUMBER: US/140,563  
14 <151> PRIOR FILING DATE: 1999-06-23  
16 <160> NUMBER OF SEQ ID NOS: 10  
18 <170> SOFTWARE: PatentIn Ver. 2.1  
20 <210> SEQ ID NO: 1  
21 <211> LENGTH: 5  
22 <212> TYPE: PRT  
23 <213> ORGANISM: Artificial Sequence  
25 <220> FEATURE:  
26 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide  
28 <220> FEATURE:  
29 <221> NAME/KEY: MISC\_FEATURE  
30 <222> LOCATION: (1)..(1)  
31 <223> OTHER INFORMATION: Xaa can be any amino acid  
34 <400> SEQUENCE: 1  
W--> 35 Xaa His Asn Pro Arg  
36 1 5  
39 <210> SEQ ID NO: 2  
40 <211> LENGTH: 5  
41 <212> TYPE: PRT  
42 <213> ORGANISM: Artificial Sequence  
44 <220> FEATURE:  
45 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide  
47 <400> SEQUENCE: 2  
48 Gln His Asn Pro Arg  
49 1 5  
52 <210> SEQ ID NO: 3  
53 <211> LENGTH: 4  
54 <212> TYPE: PRT  
55 <213> ORGANISM: Artificial Sequence  
57 <220> FEATURE:  
58 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide  
60 <220> FEATURE:  
61 <221> NAME/KEY: MISC\_FEATURE  
62 <222> LOCATION: (1)..(1)  
63 <223> OTHER INFORMATION: Xaa can be any amino acid  
66 <400> SEQUENCE: 3

→ must explain genetic source  
see error summary sheet  
item 11

## RAW SEQUENCE LISTING

DATE: 03/21/2002

PATENT APPLICATION: US/10/024,535

TIME: 10:06:35

Input Set : A:\SEQUENCE\_SMRI\_DSM.APP

Output Set: N:\CRF3\03212002\J024535.raw

W--&gt; 67 Xaa His Asn Pro

68 1

71 &lt;210&gt; SEQ ID NO: 4

72 &lt;211&gt; LENGTH: 4

73 &lt;212&gt; TYPE: PRT

74 &lt;213&gt; ORGANISM: Artificial Sequence

76 &lt;220&gt; FEATURE:

77 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: peptide

79 &lt;400&gt; SEQUENCE: 4

80 Gln His Asn Pro

81 1

84 &lt;210&gt; SEQ ID NO: 5

85 &lt;211&gt; LENGTH: 6

86 &lt;212&gt; TYPE: PRT

87 &lt;213&gt; ORGANISM: Artificial Sequence

89 &lt;220&gt; FEATURE:

90 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: peptide

92 &lt;400&gt; SEQUENCE: 5

93 Arg Gln His Asn Pro Arg

94 1 5

97 &lt;210&gt; SEQ ID NO: 6

98 &lt;211&gt; LENGTH: 11

99 &lt;212&gt; TYPE: PRT

100 &lt;213&gt; ORGANISM: Artificial Sequence

102 &lt;220&gt; FEATURE:

103 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: peptide

105 &lt;400&gt; SEQUENCE: 6

106 Val Arg Gly Pro Arg Arg Gln His Asn Pro Arg

107 1 5 10

110 &lt;210&gt; SEQ ID NO: 7

111 &lt;211&gt; LENGTH: 5

112 &lt;212&gt; TYPE: PRT

113 &lt;213&gt; ORGANISM: Artificial Sequence

115 &lt;220&gt; FEATURE:

116 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: peptide

118 &lt;400&gt; SEQUENCE: 7

119 Gln His Asn Leu Arg

120 1 5

123 &lt;210&gt; SEQ ID NO: 8

124 &lt;211&gt; LENGTH: 6

125 &lt;212&gt; TYPE: PRT

126 &lt;213&gt; ORGANISM: Artificial Sequence

128 &lt;220&gt; FEATURE:

129 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: peptide

131 &lt;400&gt; SEQUENCE: 8

132 Arg Gln His Asn Leu Arg

133 1 5

136 &lt;210&gt; SEQ ID NO: 9

137 &lt;211&gt; LENGTH: 6

## RAW SEQUENCE LISTING

DATE: 03/21/2002

PATENT APPLICATION: US/10/024,535

TIME: 10:06:35

Input Set : A:\SEQUENCE\_SMR1\_DSM.APP

Output Set: N:\CRF3\03212002\J024535.raw

138 <212> TYPE: PRT  
139 <213> ORGANISM: Artificial Sequence  
141 <220> FEATURE:  
142 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide  
144 <400> SEQUENCE: 9  
145 Gly Gln His Gly Pro Arg  
146 1 5  
149 <210> SEQ ID NO: 10  
150 <211> LENGTH: 6  
151 <212> TYPE: PRT  
152 <213> ORGANISM: Artificial Sequence  
154 <220> FEATURE:  
155 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide  
157 <400> SEQUENCE: 10  
158 Gly Gln His Asp Pro Thr  
159 1 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/024,535

DATE: 03/21/2002

TIME: 10:06:36

Input Set : A:\SEQUENCE\_SMR1\_DSM.APP

Output Set: N:\CRF3\03212002\J024535.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:35 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1

L:67 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3